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Abstract
Background: Recent studies show that transcriptional activation of GTP cyclohydrolase I (GCH1)
in dorsal root ganglia (DRG) is significantly involved in the development and persistency of pain
symptoms. We thus hypothesize that neuropathic pain may be attenuated by down-regulation of
GCH1 expression, and propose a gene silencing system for this purpose.
Results: To interrupt GCH1 synthesis, we designed a bidirectional recombinant adeno-associated
virus encoding both a small hairpin RNA against GCH1 and a GFP reporter gene (rAAV-shGCH1).
After rAAV-shGCH1 was introduced into the sciatic nerve prior to or following pain-inducing
surgery, therapeutic efficacy and the underlying mechanisms were subsequently validated in animal
models. The GFP expression data indicates that rAAV effectively delivered transgenes to DRG.
Subsequently reduced GCH1 expression was evident from immunohistochemistry and western-
blotting analysis. Along with the down-regulation of GCH1, the von Frey test correspondingly
indicated a sharp decline in pain symptoms upon both pre- and post-treatment with rAAV-
shGCH1. Interestingly, GCH1 down-regulation additionally led to decreased microglial activation
in the dorsal horn, implying an association between pain attenuation and reduced inflammation.
Conclusion: Therefore, the data suggests that GCH1 levels can be reduced by introducing rAAV-
shGCH1, leading to pain relief. Based on the results, we propose that GCH1 modulation may be
developed as a clinically applicable gene therapy strategy to treat neuropathic pain.
Background
Neuropathic pain is a chronic disease caused by aberrant
pathologic features originating from tissue damage or
inflammation within related nerve systems [1]. Typical
symptoms include spontaneous pain, exaggerated
response to noxious stimuli (hyperalgesia) and pain in
response to normally innocuous stimuli (allodynia). A
number of therapeutic drugs, such as non-steroidal drugs
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(NSAIDs) and opioids, have been introduced with the
purpose of relieving symptoms [2]. Unfortunately, a sig-
nificant proportion of drug-treated patients still suffer
from pain symptoms, mainly due to a lack of response to
drugs [3,4]. Moreover, built-up tolerance to currently
available drugs has been frequently reported among
patients. Thus, rapid development of alternative therapeu-
tic strategies for these 'difficult-to-treat' pain symptoms is
essential.
A number of studies consistently suggest that gene-based
therapy holds promise as an alternative approach for
treating pain [5-7]. GTP cyclohydrolase I (GCH1) is a rate-
limiting enzyme in tetrahydrobiopterin (BH4) synthesis,
an essential cofactor for nitric oxide synthase [8]. GCH1
transcription is activated in dorsal root ganglia (DRG)
immediately after nerve injury [9]. Moreover, the enzyme
plays a crucial role in pain sensitivity and maintenance
[10]. One of the most significant findings of this study is
the direct linkage of GCH1 expression alterations as
underlying phenomena in animal models to genotypic
characteristics within the human population. Indeed,
healthy individuals with the GCH1 haplotype experi-
enced reduced GCH1 activation and lowered pain sensi-
tivity. These results suggest that GCH1 down-regulation is
a promising strategy to treat neuropathic pain with mini-
mal side-effects, which subsequently suggests the impor-
tance of developing an effective gene silencing system.
RNA interference (RNAi) is a proven selective gene silenc-
ing technique for promoting sequence-specific degrada-
tion of complementary RNA [11,12]. A double-stranded
small interfering RNA (siRNA) about 21 nucleotides in
length is identified as the effector molecule. Several stud-
ies have confirmed the therapeutic potential of synthetic
siRNA-based strategies in neurodegenerative diseases
[2,13,14]. To sustain pain-attenuating effects via the
down-regulation of target genes, substantial levels of
siRNA are essential. However, gene knockdown effects
only last for a few days, largely due to the rapid decay of
siRNA within cells [15]. Paddison and colleagues sug-
gested the possibility of intracellular siRNA synthesis for
longer lasting gene regulating effects by simply introduc-
ing a short-hairpin RNA (shRNA) construct into cells
encoding corresponding siRNA information under con-
trol of the endogenous RNA polymerase promoter region
[16]. In addition, recombinant adeno-associated virus
(rAAV), particularly serotype 2 (rAAV2), is an excellent
gene delivery vehicle for long-term transgene expression
in post-mitotic neural cells [17,18]. Using a rat animal
model, we previously demonstrated that rAAV2 induces
therapeutic gene expression in DRG and subthalamic
nucleus in the brain over several months [19,20]. In this
regard, rAAV is a promising vector for the development of
gene-based therapy for neuropathic pain.
In the present study, we constructed a rAAV2 harboring
the shRNA sequence corresponding to GCH1 siRNA to
validate its therapeutic potential in the treatment of pain
symptoms. Using an animal pain model, we provide evi-
dence that downregulation of GCH1 by shGCH1 via rAAV
delivery is readily achieved, and leads to relief of neuro-
pathic pain. Accordingly, we propose that suppression of
GCH1 using rAAV is a promising gene-based strategy to
treat chronic pain.
Results
Effects of gene silencing of rat GTP cyclohydrolase 
(rGCH1) with siRNA and shRNA
For knockdown of rGCH1 expression, nine siRNAs target-
ing various rGCH1 exon regions were designed (Fig. 1).
The GCH1 silencing effect was examined using 293T cells
exogenously expressing rGCH1, which were transfected
with rGCH1-specific or control non-specific siRNA. West-
ern-blotting analysis revealed that all specific siRNAs
markedly inhibited rGCH1 expression, while control siR-
NAs did not. For further analysis, we selected a siRNA
sequence targeting exon 4 of rGCH1 and generated a
shGCH1 construct expressing shRNA under the control of
a H1 promoter [15]. As expected, shGCH1 dramatically
suppressed rGCH1 expression, similar to its correspond-
ing siRNA (Fig. 2a). To achieve persistent shRNA expres-
sion, we constructed rAAV-shGCH1 by inserting this
shGCH1 expression cassette into the rAAV2 backbone.
siRNAs specific for GCH1 and their gene silencing effect Figure 1
siRNAs specific for GCH1 and their gene silencing 
effect. In the presence of rGCH1 expression vector 
(pcDNA3-rGCH1), 293T cells were transfected either 
scrambled control or rGCH1-specific various siRNAs. Two 
days after transfection, cells were harvested and western-
blotting was carried out. The data revealed a significant 
decrease in the rGCH1 level is observed when siRNAs for 
rGCH1 are present.
siRNAs Target sequence (5’-3’) Start (nt) GC (%)
1 scrambled AUUCUAUCACUAGCGUGAC - 42.1
2 rGCH1-ex 1 CCAUGCAGUUCUUCACCA 275 47.4
3 rGCH1-ex 1-2 AGGGAUACCAGGAGACCA 293 49.2
4 rGCH1-ex 2 UGUCCUGAACGAUGCUAUA 318 42.1
5 rGCH1-ex 3 GUCCAUAUUGGUUAUCUUC 427 36.8
6 rGCH1-ex 4 GUGGAAAUCUACAGUAGAA 487 36.8
7 rGCH1-ex 5-1 UUCAAGAACGCCUUACCAA 515 42.1
8 rGCH1-ex 5-2 UCAAGAACGCCUUACCAAA 516 42.1
9 rGCH1-ex 6-1 UGCAGAAAAUGAACAGCAA 656 36.8
10 rGCH1-ex 6-2 CAGAAAAUGAACAGCAAGA 658 36.8
rGCH1 (less exposure)
ƅ-actin 
siRNAs specific for rGCH1
rGCH1 (longer exposure)
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rAAV-shGCH1 additionally encodes the GFP reporter
gene driven by the CMV promoter to allow the simultane-
ous tracking of shGCH1 expression (Fig. 2b). rAAV-GFP
lacking the shGCH1 expression cassette was employed as
a control. The rGCH1 silencing effect was viral dose-
dependent in HeLa cells (Fig. 2c). As expected, the rGCH1
level was not affected by the control virus. A similar degree
of GFP expression was observed with equivalent amounts
of either virus. Our data collectively suggest that rAAV-
mediated shGCH1 synthesis effectively suppresses GCH1
expression.
Delivery of rAAV-mediated shGCH1 into dorsal root 
ganglion (DRG)
Recent studies propose that sciatic nerve injection of
rAAVs is a promising strategy for delivery of therapeutic
genes to DRG [21,22]. In view of these findings, we
attempted to deliver transgenes into DRG by administer-
ing 6.0 × 107 of rAAV-shGCH1 or rAAV-GFP to the sciatic
nerve 9 days after spared nerve injury (SNI). Gene transfer
efficiency was confirmed by the presence of GFP-positive
DRG neural cells under a fluorescent microscope (Fig. 3).
Intense green signals were discerned in all infected mice
from both experimental groups on day 14 post virus injec-
tion (n = 4 for each group), indicative of effective GFP
transgene expression. In contrast, green fluorescence was
absent in control groups (n = 5). In equivalent experi-
ments involving treatment with viruses prior to pain sur-
gery, we observed analogous patterns of notable GFP
expression in experimental groups (data not shown). The
data confirm that the sciatic nerve is a useful delivery
route for transducing the DRG with the genes of interest,
in both cases of pre- and post-injection.
Attenuation of neuropathic pain behavior through 
downregulation of GCH1 levels via rAAV-shGCH1
Spared nerve injury was generated by tight ligation and
transaction of the tibial and common peroneal nerves
while leaving sural nerves intact [23], and promptlly
developed pain behavior which was determined by
mechanical von Fray threshold. Following surgery, the
mechanical threshold began to drop sharply from normal
range to pain threshold levels (Fig. 4). All the animals
showed pain symptoms within few days which were
maintained thereafter (on day 7; 2.2 ± 0.9 at the threshold
level). To explore the beneficial effects of GCH1 down-
regulation on neuropathic pain, related behavior was ini-
tially examined under blinded conditions. After introduc-
ing rAAV-shGCH1 (n = 10) or control rAAV-GFP (n = 10)
into rats (9 days post pain surgery), the mechanical von
Fray test was performed at the designated time-points. As
shown in Fig. 5, the average von Fray threshold was 2.8 ±
0.3 at the threshold level on day 9 after pain surgery. Fol-
lowing rAAV-shGCH1 treatment, the pain threshold grad-
ually declined over time, except in the case of rAAV-GFP
as expected. To ensure that GCH1 down-regulation was
specifically promoted by rAAV-shGCH1, GCH1-specific
immunohistochemistry and western-blotting assay was
performed in ipsilateral L4/5 DRGs. In immunohisto-
chemistry, shGCH1 introduction via rAAV2 significantly
suppressed GCH1 expression to a similar level as the no-
pain control group, while the up-regulation of GCH1
remained unchanged in the rAAV-GFP injected group
(Fig. 6a), which supports previous report showing the
positive association of pain symptoms with GCH1 activa-
tion [10]. The relative GCH1 levels were 2.3 ± 0.4 and 1.2
± 0.3 in GFP- and shGHC1-treated pain groups, respec-
tively (Fig. 6b). In addition, the immunohistochemical
staining against GCH1 showed a prominent negative cor-
relation with the mechanical threshold of respective ani-
mals (Spearman rho test, Correlation coefficient = -
0.470), though there was no statistical significance mainly
due to small sample numbers. Similar pattern of GCH1
expression was also observed in western-blotting analysis
(Fib. 6c). These results collectively illustrate that rAAV-
shGCH1 treatment of the sciatic nerve effectively sup-
presses GCH1 expression and leads to effective pain relief.
As predicted, injection of rAAV-shGCH1 prior to SNI pre-
vented pain induction whereby several rats experienced
no differences in the pain test compared to control ani-
mals (Fig. 7). Similar to post-injection, the anti-pain effect
rAAV constructs and its gene silencing effect Figure 2
rAAV constructs and its gene silencing effect. (a) 293T 
cells were co-transfected with or without shGCH1 
(pshGCH1) in the presence of pcDNA3-rGCH1 for two 
days. (b) Schematic illustration of rAAVs encoding GFP and 
shGCH1; GFP and shGCH1 expression cassettes were 
located in opposite directions to minimize interference with 
each other. (c) HeLa cells were co-treated with pcDNA3-
rGCH1 and rAAV at the designated multiplicity of infection 
(MOI) for two days. Western-blotting analyses revealed a 
significant decrease in the rGCH1 levels in the presence of 
shGCH1. MT; mock-treated. ITR; internal terminal repeat of 
rAAV.
(a)
rAAV-shGCH1
(b)
(c)
rAAV-GFP
ƅ-actin
GCH1
GFP
rAAV-GFP rAAV-shGCH1
10 100 1000 10 100 1000 (MOIs)
pH1 shGCH1
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ITR ITR
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GFP pCMV polyA
ƅ-actin 
rGCH1
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upon pre-treatment reached maximal levels on day 14
after virus injection. In conjunction with data obtained
from Fig. 3, these results suggest that shGCH1 introduc-
tion into the sciatic nerve via rAAV2 delivery leads to
marked attenuation of pain symptoms, regardless of treat-
ment times.
Suppression of inflammation activation by AAV-shGCH1
Previous studies have demonstrated that inflammatory
activation of microglia in the ipsilateral spinal cord plays
a crucial role in the development of neuropathic pain
[24]. To determine whether GCH1 downregulation affects
microglial activation, we performed immunohistochem-
istry with the Iba-1 antibody, a microglial marker (Fig. 8).
Indeed, nerve injury activated microglia, as evident from
both the increased number and the morphological
changes of microglia in the ipsilateral dorsal horn (data
not shown). The GFP pain group experienced similar
microglial alterations. In contrast, microglial activation
was significantly inhibited in the shGCH1 pain group,
and a similar pattern of microglial inactivation was
observed in case of virus pre-treatment. These results sug-
gest that pain attenuation following shGCH1 introduc-
tion is associated with a decrease in inflammation.
Discussion
The present study provides clear evidence of the therapeu-
tic potency of GCH1 down-regulation in DRG via rAAV-
shGCH1-mediated silencing for treating neuropathic
pain. Initially, we confirmed that the sciatic nerve is an
effective route for rAAV to transduce primary sensory neu-
rons residing in ipsilateral DRG. shGCH1/siGCH1 was
effectively synthesized in neural cell bodies of DRG and
Efficient gene delivery into DRG through sciatic nerve injection Figure 3
Efficient gene delivery into DRG through sciatic nerve injection. The left sciatic nerves of rats were injected with 
rAAV-GFP or rAAV-shGCH1. At 14 days after injection, rats were sacrificed and L5 DRGs removed following perfusion. DRG 
tissue sections were prepared at a thickness of 10 μm. Fluorescent green signals were identified as GFP expression in both 
virus-treated groups under a fluorescent microscope. Scale bar = 100 μm.
rAAV-shGCH1 rAAV-GFP Normal
Mechanical pain development following pain injury Figure 4
Mechanical pain development following pain injury. 
Spared nerve injury was operated by tightly ligating and 
transectioning the tibial and common peroneal nerves and 
leaving sural nerves intact. As shown here, the animals 
promptlly developed pain behavior that was determined by 
mechanical von Fray threshold.
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actively degraded GCH1 mRNA and disrupted protein
synthesis. Decreased GCH1 expression was linked with
the acquisition of pain resistance and decrease of micro-
glial inflammation in the corresponding spinal cord.
GCH1 is the rate-limiting enzyme during the de novo syn-
thesis of tetrahydrobiopterin (BH4), an essential cofactor
for the formation of nitric oxide, biogenic amines and
serotonin [8]. Hereditary diseases, such as DOPA-respon-
sive dystonia and atypical phenylkenonuria, are attrib-
uted to GCH1 mutations [25]. However, recent evidence
implies that genetic alterations in GCH1 have effects
beyond 'loss-of function'-related symptoms. Among
these, reduced pain hypersensitivity is evident [26,27].
GCH1 haplotypes comprising of 15 SNPs are associated
with reduced pain symptoms [25], although conflicting
reports are documented [28]. Our present data indicates
that blockage of GCH1 over-expression effectively attenu-
ates pain symptoms, strongly supporting previous find-
ings on the close correlation between GCH1 down-
regulation and pain relief.
Certain small molecules, such as the GCH1 inhibitor, 2-4-
diamino-6-hydroxypyrimidien (DAHP), have been found
to rapidly ameliorate pain symptoms in animal models
[10]. However, DAHP usage in clinical situations is lim-
ited by its cytotoxicity and short-term effectiveness (last-
ing only a few hours). In this regard, rAAV-shGCH1 is
Attenuation of neuropathic pain behavior upon post-injec- tion with rAAV-shGCH1 Figure 5
Attenuation of neuropathic pain behavior upon post-
injection with rAAV-shGCH1. Pain hypersensitivity of 
the rats was measured using up-and-down methods with the 
von Frey filaments on the designated days. Values below the 
broken line (threshold = 4) represent pain-like behavior. 
Data are presented as means ± SEM (n = 10 for rAAV-
shGCH1 and rAAV-GFP- injected pain groups; n = 6 for the 
normal control group). An asterisk (*) indicates that the 
rAAV-shGCH1-injected group significantly differs from the 
rAAV-GFP-injected group (*p < 0.05). black square, rAAV-
GFP; open square, rAAV-shGCH1.
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Downregulation of the rGCH1 level by rAAV-
shGCH1 in ipsilateral DRG. Immunohistochemistry (a, b) 
and western-blotting analysis (c) using GCH1-specific pri-
mary antibody allowed the visualization of rGCH1 expres-
sion 14 days after virus administration. Secondary antibody 
conjugated with Alexa Fluor-555 was used. The relative 
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immune-positive cells following immunohistochemistry (b). 
Data are presented as means ± SEM (n = 8 per each groups). 
*p < 0.05, Scale bar = 100 μm.
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Comparison of pain relief following pre- and post-injection of  rAAV-shGCH1 Figure 7
Comparison of pain relief following pre- and post-
injection of rAAV-shGCH1. For pre-injection of rAAV, 
viruses were introduced into the sciatic nerve 7 days before 
surgery, and at 9 days after surgery. Pain behavior was esti-
mated on day 14 after virus injection, as described in Fig. 3. 
Values below the broken line (threshold = 4) represent pain-
like behavior. An asterisk indicates that the rAAV-shGCH1-
injected group differs significantly from the rAAV-GFP-
injected group (* p < 0.05; ** p < 0.001).
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superior as a novel therapeutic agent. shGCH1 can exclu-
sively disrupt target GCH1 mRNA, facilitating a specific
gene knockdown effect. Additionally, rAAV2 is an excel-
lent gene delivery system for neural tissues [29]. Transduc-
tion of neural cells by rAAV is efficient and persistent with
minimal toxicity. In our study, a single injection of the
virus led to consistent down-regulation of GCH1 expres-
sion following pain surgery, and improved pain resistance
over time. Thus, local synthesis of shGCH1 via rAAV in
DRG may offer clinical benefits. The clinical potential of
rAAV to treat several neurodegenerative diseases is cur-
rently under investigation in human trials [30,31].
One of the major advantages of gene-based therapy is its
high efficacy and minimal side-effects, which is essentially
achieved by the specific transduction of target cells/tissues
in a regionally concentrated manner. Several studies have
described the successful achievement of local gene expres-
sion in the DRG/dorsal horn through various routes [22].
The most well-established and direct technique is the
administration of the vector into DRG itself. However,
this method requires invasive surgery requiring the
removal of a part of the spinal vertebra [19], which can
result in unwanted nerve injury and side-effects. Intrathe-
cal administration is an alternative method. However, its
usefulness is limited by reduced effectiveness of gene
transfer and poorer target specificity. In contrast, sciatic
nerve injection is an attractive strategy [21]. Virus admin-
istration to the sciatic nerve is not as invasive as direct
injection, and applicable in clinical situations. Consistent
with other related studies, our data suggests that rAAV2-
mediated gene delivery via the sciatic nerve effectively dis-
tributes the transgene to DRG, leading to successful acqui-
sition of therapeutic activity with confirmed neuronal
tropism. Hence, the sciatic nerve is an excellent route for
local treatment of the DRG/spinal dorsal horn when rAAV
is employed as a gene delivery vehicle.
As an additional advantage, we noted that shGCH1 treat-
ment led to decreased activity of microglial cells which
play a key role in inflammatory events associated with
pain symptoms. Inflammatory events through the phos-
phorylation of signaling mediators in the p38 MAPK
pathway are well documented during clinical pain devel-
opment in various types of pain [24]. As key players in this
event, microglial cells proliferate and undergo morpho-
logical alterations to their active forms in the ipsilateral
dorsal horn of the spinal cord [32,33]. Microglial cells
exhibit abnormally hyper activities--including phagocytic
properties, secretion of neurotrophic factors, and
cytokines--following the stimulation of the p38 phospho-
rylation signal within 3 days after nerve injury in an ani-
mal model [34,35]. Microglial activation, in turn,
aggravates pain development and other related symp-
toms. Therefore, it is also vital to mitigate microglial
inflammation for an effective pain cure. Interestingly, we
observed that shGCH1 introduction significantly reduced
microglial activation, regardless of the time-point after
nerve injury. Finally, it is very interesting issue to verify
long-term effects of GCH1 down-regulation especially
focusing on modulation of microglial activation in spinal
cord. In this regard, further studies are warranted to inves-
tigate the mechanism by which activated microglia in spi-
nal cord might be associated with GCH1 expression and
then participate in the initial development and/or persist-
ence of pain. Efforts to exploring the inter-relationship
between GCH1 expression and microglial activation may
pave the way to develop new therapeutic modalities for
neuropathic pain.
Based on these findings, we propose that: i) up-regulation
of GCH1 following nerve injury is associated with inflam-
matory activation of microglia and development of pain;
and ii) GCH1 down-regulation alters microglial activa-
tion patterns, and subsequently leads to relief of pain
symptoms.
Methods
Cell culture
293T and HeLa cells were purchased from the American
Type Culture Collection (Manassas, VA). Cells were main-
tained in Dulbecco's modified Eagle's medium (Gibco
BRL, Carlsbad, CA) supplemented with 10% fetal bovine
serum, L-glutamine (2 mM), penicillin (100 IU/ml) and
streptomycin (50 μg/ml) at 37°C in a 5% CO2 incubator.
Inhibition of microglial activation via rAAV-shGCH1 in the  spinal cord dorsal horn Figure 8
Inhibition of microglial activation via rAAV-shGCH1 
in the spinal cord dorsal horn. Nissl-staining was carried 
out in the frozen sections of spinal cords. Microglia in the spi-
nal cord dorsal horn were visualized with the Iba-1 primary 
antibody on day 14 after either pain surgery for pre-treat-
ment and virus administration for post-treatment. Immuno-
histochemistry data reveal that the number of Iba-1 positive 
cells increased in the rAAV-GFP pain group only. Scale bar = 
100 μm.
Nissl (Ipsilateral) Pre-treatment
Normal
rAAV-GFP rAAV-shGCH1 
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siRNA preparation and treatment
All siRNAs against GCH1 were designed using software
from MWG Biotech AG http://www.mwg-biotech.com. In
total, nine duplex siRNAs (Supple. 1) with a dTdT 3' over-
hang and control scrambled siRNA were manufactured by
DHARMACON (Lafayette, CL) with the "ready-to-use"
option. Cells were transfected with 100 nM siRNA com-
plexed with Oligofectamine reagent (Invitrogen,
Carlsbad, CA) in OPTI-MEM medium (Invitrogen). After
3 h, media were replaced with growth medium containing
10% serum. The next day, cells were harvested and
extracted for Western blotting.
Construction of a bidirectional shRNA expression vector
The human H1 polymerase III promoter (pH1) for shRNA
expression was amplified from HeLa cells using PCR-
based methods, as described previously [36]. The shRNA
sequences against rGCH1 (shGCH1) are 5'-GAT CCC
GTG GAA ATC TAC AGT AGA ATT CAA GAG ATT CTA
CTG TAG ATT TCC ACT TTT TTG GAA A-3' (sense) with a
BamHI linker and 5'-AGC TTT TCC AAA AAA GTG GAA
ATC TAC AGT AGA ATC TCT TGA ATT CTA CTG TAG ATT
TCC ACG-3' (anti-sense) with a HindIII linker. Nucle-
otides specific for rat GCH1 are underlined, and the loop
structures presented in bold. The pH1-shGCH1 sequence
was inserted adjacent to the CMV promoter of the vector
expressing GFP, resulting in a bi-directional promoter
(Figure 1a). All clones were verified by sequencing (data
not shown).
Preparation of rAAV containing shGCH1
To produce rAAV2, the viral backbone, pH1-shGCH1-
pHpa-trs-SK, was co-transfected with pRepCaps and pXX6
(Stratagene, La Jolla, CA) encoding adenoviral helper
genes [37,38]. For large-scale rAAV preparations, 293T
cells were transfected in 20 × 10 cm dishes. rAAVs in cells
were released and purified from cell lysates (including
supernatant fractions) using two sequential CsCl gradient
steps. After dialysis in 10 mM Tris buffer (pH 7.9) contain-
ing 2 mM MgCl2 and 2% sorbitol, rAAVs were aliquoted
and stored at -80°C. The number of total virus particles
was estimated with an ELISA kit (Progen Inc., Heidelberg,
Germany) and real-time qPCR, as described in a previous
report [38].
Animal care and virus administration
Adult male Sprague Dawley rats weighing 180-200 g were
housed with free access to food and water. With the
approval of the University committee on the use and care
of animals, rats were maintained in an optimal tempera-
ture and humidity-controlled room with a 12 hr light/
dark cycle.
To inject rAAVs to the sciatic nerve, rats were anesthetized
with Zoletil (50 mg/kg) and Rompun (10 mg/kg). Next, a
segment of the left sciatic nerve was exposed at the mid-
thigh level. Surrounding tissues were carefully removed
under a surgical microscope, exposing sciatic nerve
exposed (Olympus, Japan). A 3 μl viral solution contain-
ing rAAV-shGCH1 (6.0 × 106 viruses in 3 μl) or rAAV-GFP
(4.0 × 106 viruses in 3 μl) was slowly injected into the
nerves through a glass micropipette connected to a Ham-
ilton syringe for 5 min. The pipette was pulled out after 5
min.
SNI model and behavior test
To generate the spared nerve injury (SNI) model, the com-
mon peroneal and tibial nerves were tightly ligated and
completely transected while the sural nerve was left intact
[39]. Mechanical allodynia in rats was assessed by apply-
ing a series of Von Frey filaments to the plantar surface of
the hind paw (range 0.01 - 1.66 g) in ascending and
descending order (up-and-down method). Brisk with-
drawal of the hind limb was considered a positive
response. A withdrawal threshold of 4.0 g or less was clas-
sified as allodynia (pain-like behavior).
Western- blotting
L4-5 DRG tissues were homogenized with lysis buffer con-
taining 10 mM Tris-HCL (pH 8.0), 150 mM NaCl, 1% Tri-
ton-X100 and protease inhibitor cocktails (Sigma, St.
Louis, MO), and centrifuged for 30 min at 4°C. Lysates
(10-40 μg of proteins per lane) were separated by 10%
SDS-PAGE and transferred onto PVDF membranes (Bio-
Rad, Hercules, CA). Blots were incubated with the speci-
fied primary antibodies. The following antibodies were
used: GCH1 (Abnova, Taiwan), β-actin (Sigma), and GFP
(Santa Cruz Biotechnology, Santa Cruz, CA). Following
incubation with peroxidase-conjugated anti-mouse (or
anti-goat) IgG (Vector Laboratories, Burlingame, CA),
proteins were detected using the chemiluminescence
method (Pierce, Rockford, IL).
Nissl staining & Immunohistochemistry
Frozen tissue sections of 10  m in thickness were prepared and
Nissl-staining was carried out, as described previously [40].
Immunostaining was also performed using frozen sec-
tion. Briefly, after perfusion with 4% paraformaldehyde,
DRG (L4, L5) and spinal cord (T13-L2) were removed and
cryoprotected in 30% sucrose solution (dissolved in phos-
phate-buffered saline) for 24 h at 4°C before embedding
in OCT compound (Sakura Finetek, Torrance, CA). Sec-
tions were incubated at 4°C with primary antibodies over-
night. Antibodies used for immunohistochemistry were as
follows: GCH1 (Abnova), NeuN (Chemicon, Temecula,
CA), Iba-1 (Wako, Japan), phosphor-p38 (Cell signaling
Technology, Beverly, MA), and OX-42 (Chemicon). Sec-
tions were subsequently incubated with Alexa 488-conju-
gated (or Alexa 555) secondary antibodies at room
temperature for 60 min. After mounting using VectashieldMolecular Pain 2009, 5:67 http://www.molecularpain.com/content/5/1/67
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with DAPI (Vector laboratories), images were observed by
fluorescence microscopy (Leica, Germany).
Statistics
All data were expressed as means ± SEM of three or more
independent experiments. The statistical significance of
differences between the values was determined by two-
sample comparisons made using the 2-tailed t test or one-
way ANOVA (analysis of variance) and post Dunnett's
multiple comparison test. Statistical tests were performed
using PRISM (GraphPad Software, San Diego, CA, USA).
Differences were considered significant at P values less
than 0.05.
Conclusion
We have confirmed the therapeutic potential of shRNA-
induced GCH1 down-regulation via rAAV in neuropathic
pain treatment using the sciatic nerve as a delivery route.
Consistent with previous reports showing beneficial
effects on pain relief in patients with GCH1 genetic disor-
ders, our findings strongly suggest that GCH1 modulation
can be effectively developed as a clinically applicable gene
therapy strategy to treat neuropathic pain.
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